Reduced 3-O-methyl-dopa levels in OCD patients and their unaffected parents is associated with the low activity M158 COMT allele. by Delorme, Richard et al.
Reduced 3-O-methyl-dopa levels in OCD patients and
their unaffected parents is associated with the low
activity M158 COMT allele.
Richard Delorme, Catalina Betancur, Pauline Chaste, Solen Kerne´is, Astrid
Stopin, Marie-Christine Mouren, Corinne Collet, Thomas Bourgeron, Marion
Leboyer, Jean-Marie Launay
To cite this version:
Richard Delorme, Catalina Betancur, Pauline Chaste, Solen Kerne´is, Astrid Stopin, et al.. Re-
duced 3-O-methyl-dopa levels in OCD patients and their unaffected parents is associated with
the low activity M158 COMT allele.. American Journal of Medical Genetics Part B: Neu-
ropsychiatric Genetics, Wiley, 2010, 153B (2), pp.542-8. <10.1002/ajmg.b.31016>. <inserm-
00474052>
HAL Id: inserm-00474052
http://www.hal.inserm.fr/inserm-00474052
Submitted on 10 Nov 2011
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.

Delorme 1 
Reduced 3-O-methyl-dopa levels in OCD patients and their 
unaffected parents is associated with the  
low activity M158 COMT allele 
 
Richard Delorme,*
,1,2,3
 Catalina Betancur,
4,5
 Pauline Chaste,
2,3
 Solen Kernéis,
6
 Astrid 
Stopin,
1,7
 Marie-Christine Mouren,
3
 Corinne Collet,
8
 Thomas Bourgeron,
3
 Marion 
Leboyer,
1,7,9
 and Jean-Marie Launay
8
 
 
1 
INSERM U955, Institut Mondor de Recherche Biomedicale, Psychiatric Genetics, Créteil, 
France 
2 
APHP, Hôpital Robert Debré, Child and Adolescent Psychiatry, Paris, France  
3 
Pasteur Institute, Human Genetics and Cognitive Functions, Paris, France  
4 
INSERM U952, Paris, France  
5 
Université Pierre et Marie Curie, Paris, France  
6
 APHP, Groupe Hospitalier Cochin-Saint Vincent de Paul, Cochin-Pasteur Vaccinology 
Center, Paris, France. 
7
 APHP, Groupe Hospitalier Henri Mondor - Albert Chenevier, Department of Psychiatry, 
Créteil, France  
8 
APHP, Hôpital Lariboisière, Department of Biochemistry, Paris, France  
9
 Université Paris 12, Medical School, Créteil, France 
 
Correspondence to: Dr. Richard Delorme, Child and Adolescent Psychiatry, Hôpital Robert 
Debré, 48 Boulevard Serurier, 75019 Paris, France, Tel: +33 140032300, Fax: +33 
140032297, E-mail: richard.delorme@rdb.aphp.fr 
 
 
Running Title: Reduced 3-O-methyl-dopa levels in OCD 
Delorme 2 
Background: The catechol-O-methyltransferase (COMT) gene is considered as a candidate 
gene in obsessive-compulsive disorder (OCD). Specifically, the COMT low-activity M158 
allele has been suggested to be associated with OCD. However, there is no study reporting 
that COMT activity is decreased in OCD patients and that the decrease is mediated by the 
V158M polymorphism. Therefore, the purpose of our study was to assess COMT activity in 
OCD by measuring plasma levels of 3-O-methyl-dopa (3-OMD), which result from the 
methylation of levodopa by COMT, and to investigate the relationship between 3-OMD levels 
and the V158M polymorphism. We also examined whether 3-OMD levels represented an 
endophenotype, associated with the genetic liability to OCD, by assessing unaffected relatives 
of OCD patients.  
Method: We assessed plasma 3-OMD levels in a sample of drug-free OCD probands (n = 34) 
and their unaffected parents (n = 63), and compared them with controls (n = 85). The COMT 
V158M polymorphism was genotyped in all participants.  
Results: Lower plasma 3-OMD levels were found in OCD probands and their unaffected 
parents compared to controls. The COMT M158 allele was associated with reduced plasma 3-
OMD levels in a co-dominant manner, both in OCD probands and their relatives, but not in 
controls.  
Conclusion: Our results suggest that COMT activity could act as a limiting factor for the 
production of 3-OMD in OCD patients and in their relatives. These findings further support a 
role of COMT in the susceptibility to OCD and provide evidence that 3-OMD levels could 
represent an endophenotype in OCD.  
 
Key words: anxiety, gene, dopamine, phenotype, methyl-transferase 
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INTRODUCTION 
Obsessive-compulsive disorder (OCD) is characterized by recurrent and intrusive thoughts 
and ritualistic behaviors or mental acts that a person feels compelled to perform. Although the 
etiology of the disorder remains largely unknown, evidence from familial, twin and 
segregation studies supports that OCD has a strong genetic component [Samuels et al., 2007]. 
The catechol-O-methyltransferase (COMT) gene is considered as a candidate gene in 
OCD. Obsessive-compulsive symptoms are frequently reported in patients with the 22q11.2 
deletion syndrome (DiGeorge/velocardiofacial syndrome), up to 32% of patients meet criteria 
for OCD [Gothelf et al., 2004]. Among the genes located in the 3 Mb most frequent deletion 
is COMT, involved in the catabolism of norepinephrine and dopamine neurotransmitters 
[Guldberg and Marsden 1975, Kobrynski and Sullivan 2007]. In addition, dopamine 
abnormalities have been implicated in the pathophysiology of OCD on the basis of several 
lines of clinical evidence [Westenberg et al., 2007]. These include the high incidence of OC 
behavior in a number of basal-ganglia-related disorders, such as Tourette syndrome [Grados 
et al., 2008], changes in OC symptoms following the administration of the dopamine reuptake 
inhibitor amphetamine to OCD patients [Insel et al., 1983], and the therapeutic benefits 
obtained by co-administration of dopaminergic blockers [Bloch et al., 2006].  
The COMT gene contains a relatively frequent single nucleotide polymorphism (SNP) in 
codon 158, V158M. The enzyme coded by the M158 allele is unstable at 37°C and shows four 
times lower activity than the enzyme coded by the V158 allele [Lotta et al., 1995]. The alleles 
are co-dominant, as heterozygous individuals have enzyme activity that is midway between 
homozygous individuals [Lachman et al., 1996]. Thus, genetically determined variations in 
COMT activity might affect catabolic flux of synaptic dopamine specifically in the prefrontal 
cortex in contrast to the striatum [Yavich et al., 2007]. Whereas in the striatum dopamine 
overflow is controlled by reuptake by the dopamine transporter, in the prefrontal cortex the 
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density of the dopamine transporter is much lower and dopamine elimination is mainly 
regulated by COMT. Accordingly, a recent study reported that the load of the low-activity 
M158 allele predicted enhanced prefrontal activity, especially in subjects with temperamental 
inflexibility [Drabant et al., 2006]. Thus, the high medial frontal cortex activity observed in 
OCD patients [Yücel et al., 2007] might be partially linked to the association observed 
between OCD and the low-activity M158 allele [Pooley et al., 2007]. However, there is no 
study reporting that COMT gene activity, as measured by a peripheral dopamine metabolite, is 
decreased in OCD patients and that the decrease is mediated by the V158M polymorphism. 
Furthermore, the association between the M158 COMT allele and OCD remains uncertain and 
the results are complicated by possible gender differences. The association reported by Pooley 
et al. [2007] was observed only in males, and a meta-analysis of all published case-control 
data also revealed an association between COMT M158 and OCD in men but not in women 
[Pooley et al., 2007]. However, an earlier meta-analysis failed to support an association 
between COMT and OCD [Azzam and Mathews, 2003].  
In this study, we first explored the relationship between plasma 3-O-methyl-dopa (3-
OMD) levels, resulting from the methylation of levodopa by COMT, and OCD. We 
hypothesized that plasma 3-OMD levels, reflecting COMT activity, would be decreased in 
OCD patients when compared to healthy volunteers. We then tested if the decrease in plasma 
3-OMD levels would also be observed in the parents of OCD probands. We hypothesized that 
if COMT activity is genetically mediated, plasma 3-OMD levels would also be decreased in 
the unaffected parents of OCD patients. Finally, we explored the relationship between plasma 
3-OMD levels and the COMT V158M polymorphism. We hypothesized that the M158 allele 
would be associated in a co-dominant manner to diminished 3-OMD plasma levels as 
previously observed in vitro [Weinshilboum and Raymond 1977]. 
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MATERIALS AND METHODS 
Subjects 
Thirty-four drug-free OCD probands meeting DSM-IV criteria were recruited from two 
university affiliated psychiatry departments for children (Robert Debré hospital, Paris, 
France) and adults (Mondor - Chenevier hospitals, Créteil, France). The clinical and 
demographic characteristics of OCD probands are shown in Table 1. Lifetime psychiatric 
history was evaluated during a direct interview, either with the Diagnostic Interview for 
Genetic Studies (DIGS) [Nurnberger et al., 1994] for patients over the age of 17 years, or 
with the Kiddie Schedule for Affective Disorders and Schizophrenia - Epidemiologic version 
(K-SADS-e) [Orvaschel et al., 1982] for those aged under 17 years. The severity of the OC 
symptoms at the time of inclusion was scored with the Yale-Brown Obsessive Compulsive 
Scale [Goodman et al., 1989] (Table 1). To be included in the study, patients had to have 
OCD as their main disorder, with no associated depression at the time of inclusion, and have 
been drug-free for at least eight weeks, currently admitted as a wash-out period 
In addition, 63 parents of OCD probands were also included in the study (Table 1). All 
parents were directly interviewed with the DIGS. Parents found to have a lifetime history of 
OCD, a mood disorder at the time of the interview, or who had taken a psychotropic 
treatment during the past eight weeks, were excluded from the study. 
Controls (n=85) were healthy volunteers recruited among blood donors at the Mondor 
Hospital in Creteil (Table 1). They were included after being interviewed with the French 
version of the DIGS and the Family Interview for Genetic Studies [Maxwell ME. 1992] to 
confirm the absence of both personal and family history of psychiatric disorders in first- and 
second-degree relatives. To minimize the possibility of psychiatric morbidity among subjects 
in the control group, only blood donors aged over 35 years were included. All patients, 
parents, and controls were Caucasian. The local Research Ethics Board approved the study 
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protocol. Written informed consent was obtained from all participating subjects. If the 
proband was under 18 years old, the proband's consent and written parental consent were 
obtained. 
 
Blood sampling 
All participants were asked to follow a diet poor in tryptophan and serotonin during two days 
before the blood sampling. Blood samples (7-10 ml) were collected between 8-10 a.m. into 
tubes containing EDTA. Plasma was prepared within two hours by centrifugation at 2000 g 
(4°C, 15 min) and stored at –80°C for a maximum of one month until used.  
 
Biochemical measurement 
The plasma concentration of 3-OMD was measured by reverse phase high performance liquid 
chromatography with electrochemical detection [Michotte et al., 1987]. 
 
Genotyping 
Genomic DNA was extracted from lymphoblastoid cell lines by use of the Nucleospin Blood 
L kit (Macherney-Nagel extraction kit, Germany). The V158M polymorphism was genotyped 
by direct sequencing. PCR products were sequenced with the BigDye Terminator Cycle 
Sequencing Kit V3.1 (Applied Biosystems, Foster City, CA, USA) in an ABI 3100 sequencer 
(Applied Biosystems).  
 
Statistical analysis 
Results are expressed as the median (Interquartile Range) for continuous variables and N (%) 
for categorical variables. All tests were two-sided at a 0.05 significance level. Deviation from 
Hardy-Weinberg equilibrium was assessed using a Person chi-square test. The effect of the 
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two main variables ‘phenotype’ (probands, relatives, controls) and ‘genotype’ (V158M, 
V158V, M158M) on plasma 3-OMD levels were assessed in three steps. First, the effects of 
phenotype on plasma 3-OMD levels were made with an analysis of covariance (ANCOVA), 
with age at interview as a covariate (age at interview differed between probands, relatives 
and controls, and was correlated to plasma 3-OMD levels). Second, the effects of genotype 
on the plasma 3-OMD levels were compared using a one-way ANOVA. Finally, the 
genotype-by-phenotype interaction was assessed by using the Pearson chi-square test since 
80% of the cells have an expected frequency of 5 or greater, and that no cell has an expected 
frequency smaller than 1.0 [Freeman and Halton, 1951]. 
To study the intra-familial correlations for plasma 3-OMD levels, we used the 
intraclass correlation method [Fisher, 1925], with 3-OMD levels as a continuous variable. All 
statistical analyses were performed with the aid of SPSS/PC+ computer software. 
 
RESULTS 
Plasma 3-OMD levels in OCD probands, their unaffected parents and controls 
The groups differed in age but not in gender. The OCD probands were younger than the 
unaffected parents and controls (Table 1). Since age showed a weak but significant 
correlation with 3-OMD levels (r=0.17, p=0.02), age was used as a covariate in tests of group 
differences. A one-way ANCOVA comparing 3-OMD levels in the three groups with age as 
a covariate showed significant group differences (F=21.1, df=2, 171, p<10
-3
) (Figure 1). The 
pair-wise comparisons revealed that probands had lower plasma 3-OMD levels than their 
unaffected parents (F=3.9, df=1, 87, p=0.02) and controls (F= 30.1, df=1, 116, p<10
-3
), and 
that unaffected parents had also lower 3-OMD level than controls (F=15.1, df=1, 138, p<10
-
3
) (Figure 1). These differences were not driven by a sex effect. Levels of 3-OMD did not 
differ between males and females among OCD probands (10.8 ± 4.4 vs 10.4 ± 5.4 ng/ml, 
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respectively; t=0.3, df=32, p=0.8), their relatives (14.4 ± 5.6 vs 12.4 ± 5.2 ng/ml, 
respectively; t=1.4, df=61, p=0.2), or controls (25.2 ± 4.1 vs 28.3 ± 4.1 ng/ml, respectively; 
t=0.6, df=83, p=0.5). In addition, we tested if the peripheral 3-OMD abnormalities observed 
in OCD probands and their parents were aggregated in OCD families. The intra-familial 
correlation was calculated in the subgroup of unaffected relatives who had a proband in the 
sample (n = 32). No significant intra-familial correlation was observed (ICC = 0.19, F=1.48, 
p = 0.1). 
 
Plasma 3-OMD levels and their relationship to the COMT V158M polymorphism  
V158M genotypes were in Hardy-Weinberg equilibrium in the three groups (OCD probands: 
Pearson χ²=2.9, df=2, p=0.2; unaffected parents: χ²=0.1, df=2, p=0.9; and controls: χ²=2.1, 
df=2, p=0.4) and did not differ significantly between groups (χ²=8.7, df=4, p=0.08) (Table 2). 
One-way ANOVA was used to compare mean plasma 3-OMD levels between genotypes 
across the sample. The 3-OMD level differed among genotypes (F=21.5, df=2, 179, p<10
-3
). 
The pair-wise comparisons revealed that M158 homozygotes had significantly lower 3-OMD 
levels than V158M heterozygotes (t=-5.3, df= 133, p<10
-3
) or V158 homozygotes (t=-6.0, 
df= 81, p<10
-3
) (MM: 10.9 ± 6.0, MV: 15.1 ± 5.2 and VV: 16.3 ± 5.5 ng/ml). 
 
Plasma 3-OMD levels, interaction between the phenotype and the genotype 
Because plasma 3-OMD levels vary according to the phenotype (probands, relatives and 
controls) and the genotype (V158M, V158V, M158M), we looked for an interaction between 
phenotype and genotype using a general linear model. Despite the interaction between the 
two variables (F=7.6, df=4, p<10
-3
), the main effects of the phenotype (F=27.8, df=2, p<10
-3
) 
and the genotype (F=23.2, df=2, p<10
-3
) remained significant. As hypothesized, the M158 
allele was associated with reduced plasma 3-OMD levels in a co-dominant manner, both in 
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OCD probands (F=34.1, df=1, 31, p<10
-3
) and in relatives (F=30.9, df=1, 60, p<10
-3
) (Table 
2). The 3-OMD concentration in OCD patients carrying the heterozygous genotype was 
midway between homozygotes (MM: 4.9 ± 2.8, MV: 12.5 ± 3.0 and VV: 16.8 ± 1.7 ng/ml). 
Surprisingly, the V158M polymorphism did not affect plasma 3-OMD levels in controls 
(F=0.9, df=1, 81, p=0.4) (Figure 1). 
 
DISCUSSION 
Despite numerous lines of evidence suggesting that COMT could be implicated in the 
pathophysiology of OCD, no previous studies tested if COMT activity was decreased in OCD 
patients and if this decrease was mediated by the COMT V158M polymorphism. The aim of 
our study was thus to measure plasma 3-OMD levels, which have long been used as an 
indirect index of COMT activity [Müller et al., 2002]. We report here for the first time 
reduced plasma 3-OMD levels in patients with OCD and in their unaffected parents compared 
to controls. Furthermore, we observed that the M158 allele was associated in a co-dominant 
manner with reduced plasma 3-OMD levels in OCD patients and in their parents but not in 
controls. This suggests that COMT activity could act as a limiting factor for the production of 
3-OMD in OCD patients and in their relatives but not in controls. 
 
3-OMD level, COMT activity and OCD 
The decreased levels of plasma 3-OMD reported in OCD patients and in their parents 
reinforce previous clinical and non clinical studies supporting a dysfunction of the dopamine 
system in OCD [Denys et al., 2004]. Although the role of 3-OMD in the brain remains 
unclear [Lee et al., 2008], 3-OMD has been extensively measured in Parkinson patients to 
explore the effect of COMT inhibitors on the availability of L-dopa in the brain. For example, 
the peripheral COMT inhibitor Entacapone improves the availability of L-dopa by 30-40% 
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and decreases in the same range the peripheral formation of 3-OMD in L-dopa-treated 
patients with Parkinson’s disease [Schrag, 2005]. Thus, the low levels of 3-OMD observed in 
OCD patients could reflect a decreased activity of COMT. As 50% of dopamine overflow in 
the prefrontal cortex results from COMT-mediated enzymatic degradation [Yavich et al., 
2007], the high medio-frontal cortex activity reported in OCD might be partially linked to the 
decreased activity of COMT. The medio-frontal hyperactivation observed in OCD patients 
seems to be associated with specific dimensions of inhibitory control, such as response 
conflict detection and resolution and sensitivity to errors [Yücel et al., 2007]. Thus, 
pharmacological agents that could stimulate COMT activity might be helpful in the treatment 
of OCD patients.  
 
3-OMD level, V158M polymorphism and OCD 
The low plasma 3-OMD level observed in OCD patients and in their parents appears to be 
mainly explained by the effect of the functional V158M polymorphism of COMT. The M158 
allele was associated in a co-dominant manner with decreased plasma 3-OMD levels in OCD 
patients and their parents, but not in controls. The reason why the V158M polymorphism 
limits 3-OMD synthesis in OCD but not in controls are unclear. The collection of the samples 
and the technical procedures were identical between groups and can not explain the 
differences observed. However, a bias in our control group can not be excluded since previous 
studies have reported that COMT activity directly measured on red blood cells is modulated 
by V158M in controls [Weinshilboum, 2006]. The possible effects of environmental factors 
or other regulatory factors acting at higher physiological levels can not be ruled out and might 
explain why COMT became limiting for the production of 3-OMD in OCD subjects and their 
parents but not in controls. The lack of intra-famialial correlation for 3-OMD level in OCD 
patients and their relatives also suggests that the inheritance of plasma 3-OMD levels may be 
Delorme 11 
non Mendelian and influenced by epigenetic or multifactorial factors. The investigation of 
COMT activity in B lymphoblastoid cell lines in future studies could help to exclude the 
effects of environmental or other physiological factors in the regulation of 3-OMD levels. 
Interestingly, our results are very similar to those showing that another methyl-transferase 
implicated in the methylation of serotonin (acetylserotonin methyltransferase, ASMT) could 
be involved in the reduced plasma melatonin levels observed in individuals with autism 
spectrum disorders [Melke et al., 2008]. Reduced plasma melatonin concentration was 
correlated with a deficit in ASMT activity in patients with autism spectrum disorders and their 
parents but not in controls. The mechanisms through which these two methyltransferases – 
very similar in their functions – might be implicated in psychiatric disorders remain unknown. 
The similarity in the dysfunctions of these enzymes in OCD and autism spectrum disorders 
might point out to a common pathway, such as epigenetic regulators, that could be implicated 
in both disorders [Tsankova et al., 2007], which share some clinical behaviors (e.g. insistence 
on sameness and repetitive behaviors) [Russel et al., 2005]. 
A recent meta-analysis revealed that the low expression M158 allele was associated with 
OCD in males but not in females [Pooley et al., 2007]. However this meta-analysis did not 
include the study by Alsobrook et al., [2002], in which M158 was associated with OCD in 
females but not in males. Although we did not observe a major gender effect on 3-OMD 
levels, the size of our sample limits our ability to sub-stratify our results according to 
genotypes to further investigate the effect of gender on our results. 
 
3-OMD: an endophenotype for OCD? 
As we hypothesized, plasma 3-OMD levels were decreased in the unaffected parents of OCD 
patients. The over transmission of the COMT low activity allele from parents to children 
[Pooley et al., 2007] could explain the observed 3-OMD level abnormalities in OCD probands 
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and in their unaffected relatives. Thus, low plasma 3-OMD levels could represent an 
endophenotype of OCD: its level is correlated with the phenotype in patients, it is modified 
among the unaffected relatives of OCD patients at a higher rate than in the general population, 
and involves the COMT V158M polymorphism [Leboyer et al., 2003; Gottesman and Gould, 
2003]. It is now established that COMT activity represents a risk factor for the dysfunction of 
the neostriatal-prefrontal circuit and is more related to the episodic and working memory 
dysfunction than to the psychiatric phenotype [Meyer-Lindenberg and Weinberger 2006]. 
This could explain the working memory deficits in the Tower of London test we reported 
recently in the unaffected parents of OCD probands [Delorme et al., 2007]. Unfortunately, 
due to the limited number of relatives that accepted to participate in all the biochemical, 
genetic and cognitive evaluations, we were unable to explore the relationship between 
genotypes, plasma 3-OMD level and Tower of London scores. 
 
Limitations  
Although non significant, differences in V158M genotype distribution between groups might 
affect our results. Specifically, the number of probands carrying the VV genotype is small. 
However, the global validity of our results is not likely to be influenced by this limited sample 
of VV probands since the effect of the V158M genotype on plasma 3-OMD levels was similar 
in probands and in relatives, and the V158M genotype distribution was comparable in 
unaffected parents and in healthy volunteers. Another limitation of our results is that we only 
genotyped the V158M polymorphism and it is now established that additional SNPs in the 
COMT gene modulate COMT activity by altering mRNA secondary structure [Nackley et al., 
2006]. Two polymorphisms, one located in the P2 promoter region (rs2097603) and one in the 
3’UTR region (rs165599), seem to affect prefrontal activity independently from the V158M 
polymorphism [Meyer-Lindenberg et al., 2006]. However, the V158M polymorphism 
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accounts for the larger effect on the overall functional state of the COMT gene. A further 
limitation is the study of a peripheral marker such as plasma 3-OMD levels, which may only 
partially reflect central nervous system processes. Finally, the use of 3-OMD as an index of 
COMT activity could be considered an additional limitation. A direct estimation of COMT 
activity needs to be performed in future works. Most studies use a radiometric assay for the 
determination of COMT activity on brain tissues or erythrocytes [Zurcher and Da Prada 
1982]. Unfortunately, we did not collect the red blood cells of our patients in our study.  
 
Conclusion 
In conclusion, our results support the evidence that COMT may play a role in the 
susceptibility to OCD. Further efforts should be made to clarify the potential implication of 
COMT in the disorder. Plasma 3-OMD levels, easy to measure in patients and relatives, may 
help to explore the heterogeneity of the OCD phenotype and delineate more homogenous 
groups that could help to conclude to the unequivocal implication of the COMT gene in OCD.  
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TITLES AND LEGENDS TO FIGURES 
 
Figure 1. Relation between plasma 3-O-methyldopa levels in drug-free OCD patients (n=34), 
their unaffected parents (n=63) and controls (n=85) and the COMT V158M polymorphism. 
Data represent distribution and mean.  
 
